Table 2.
Antihypertensive medication use change analysis
| RDN group | Sham group | |
|---|---|---|
| Baseline number of medications | 5.1 ± 1.4 | 5.2 ± 1.4 |
| 6-month number of medications | 5.0 ± 1.4 | 5.2 ± 1.6 |
| Medication change SV1 to SV2 | 18 (4.9%) | 13 (7.6%) |
| Any medication change between baseline and 6 months | 139a (38.2%) | 72a (42.1%) |
| >1 change between baseline and 6 months | 119 (32.7%) | 60 (35.1%) |
| Decreased number of medication classes or doses | 52 (14.3%) | 23 (12.8%) |
| Increased number of medication classes or doses | 31 (8.5%) | 17 (9.9%) |
| Combination of increases and decreases in class and/or dose | 56 (15.3%) | 32 (18.7%) |
| Medication change related to an adverse event or symptom change | 98 (26.9%) | 53 (31.0%) |
| Medication change related to SBP <115 mmHg | 13 (3.6%) | 2 (1.2%) |
| Medication change related to SBP increase >15 mmHg | 14 (3.8%) | 7 (4.1%) |
| Other reasons | 72 (19.8%) | 41 (24.0%) |
Data is mean (SD) or n (%).
SV, screening visit.
aFour RDN group patients and two control group patients who had no net change for the 6-month period (i.e. the same medication changed and returned to previous dose).